KZIANasdaqPharmaceutical PreparationsFiscal year ends June 30

KAZIA THERAPEUTICS LTD

Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Nov 7, 2025

$7.85+0.60 (+8.28%)

Close on Oct 19, 2026

Debt

Borrowings on the balance sheet, Dec 31, 2025

Kazia Therapeutics reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Kazia Therapeutics's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Kazia Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-5 reverse split on Apr 17, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is KZIA.

Revenue growth-98.2% · median -72.8%

Net margin-49290.5% · median -467453.1%

Company	Revenue	Growth
LSTA	$100.00K	-90.7%
KZIA	A$42.00K	-98.2%
LYEL	$27.00K	-55.0%
CNBX	$0	–
NTHI	–	–
KPRX	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: June 30
Employees: 14
Held by institutions: 0.4%
Auditor: BDO Audit Pty Ltd
SEC CIK: 1075880

Advertisement
300 × 250